Letermovir Prophylaxis Associated with Lower All-Cause Mortality Through Week 24 Post-Transplant
Company Plans to Submit New Drug Applications for Letermovir in U.S. and EU in 2017
Merck’s Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow Transplant Recipients, Highly Effective Through Week 24 Post-Transplant in Pivotal Phase 3 Study | Merck Newsroom Home
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.